Achieve Life Sciences saw its stock fall after the U.S. Food and Drug Administration issued a Complete Response Letter (CRL) for the company's New Drug Application (NDA) for cytisinicline, an investigational therapy for nicotine dependence.
The CRL identified shortcomings tied to a prior third-party manufacturing facility and noted that the final product labeling submitted with the NDA was incomplete. Importantly, the FDA did not identify any deficiencies related to the clinical efficacy or safety profile of cytisinicline.
According to company disclosures, the manufacturing issues relate to a former contract manufacturing site that received an Official Action Indicated classification from the FDA for general current Good Manufacturing Practice matters that are not specific to cytisinicline. Achieve previously disclosed that it expected the CRL on or before its June 20 PDUFA date, with the company announcing that expectation on April 15.
To address the manufacturing concern, Achieve has designated U.S.-based Adare Pharma Solutions as its new primary commercial manufacturing partner. The firm reports completion of the analytical method technology transfer to Adare's facility, the production of its first cytisinicline engineering batch at that site, and the full qualification of all testing procedures there.
Achieve plans to resubmit the NDA in the fourth quarter of 2026, listing Adare as the primary manufacturing partner. The company is targeting potential FDA approval in the first half of 2027, after which it expects to progress to a U.S. commercial launch.
The cytisinicline NDA is supported by a clinical program that exposed more than 1,500 participants to the drug. Pivotal evidence comes from the Phase 3 ORCA-2 and ORCA-3 trials, in which cytisinicline delivered significantly higher smoking abstinence rates both at the end of treatment and in sustained abstinence through week 24 compared with placebo.
Implications for stakeholders
- Biotech and pharmaceutical investors are closely watching the timeline for resubmission and the transition to a new manufacturer.
- Manufacturing and contract development organizations are highlighted in this outcome, as prior third-party facility compliance influenced regulatory clearance.
- Healthcare markets may see a delayed commercial introduction for cytisinicline if the resubmission and review follow the company's projected timeline.
Achieve's next regulatory milestone will be the formal NDA resubmission, at which point the FDA will reassess the application with Adare listed as the primary manufacturing partner. Until that submission and any subsequent agency review, the approval timeline remains contingent on Achieve's corrective actions and the completeness of labeling and manufacturing documentation.